Study of effect of curcumin in patients with Benign Prostate Hyperplasia

Study of the effect of curcumin on insulin resistance, sexual hormones and oxidative stress and inflammatory biomarkers in patients with Benign Prostate Hyperplasia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170430033730N3

Enrollment

Registered

2018-07-08

Start date

2018-05-26

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia. Enlarged prostate

Interventions

Intervention 1: Intervention group: Two capsules of 80 mg of curcumin were taken twice daily for twelve weeks. Intervention 2: Control group: Two capsules of 80 mg of placebo are given twice a day for

Eligibility

Sex/Gender

Male

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with benign prostatic hyperplasia

Exclusion criteria

Exclusion criteria: patients who do not want to cooperate patients who use anticoagulant diabetic patients patients with hypo and/or hyperthyroidism

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score (IPSS). Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Standard questionnaire for International Prostate Symptom Score evaluation.;Insulin. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Testosterone. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;DHT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Estradiole. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Angiopoitin-2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.	—

Measure

Time frame

Glutathion. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;MDA. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Testosterone. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;DHT. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Estradiole. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.;Angiopoitin-2. Timepoint: At the beginning of the study and 12 weeks after the intervention. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyyed Mehdi Mirhashemi

Qazvin University of Medical Sciences

mirhashemism@gmail.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 10, 2026